SCHEMBL594516

SCHEMBL594516

O=C(Nc1nc2ccccc2s1)Oc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCD O00767 4/20 0.69
MMP13 P45452 2/20 0.69
ALDH1A1 P00352 3/20 0.60
CYP2C19 P33261 2/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2D6 P10635 1/20 0.60
CYP2C9 P11712 1/20 0.60
ALOX15 P16050 1/20 0.60
KMT2A Q03164 4/20 0.57
MAPT P10636 3/20 0.57
NPC1 O15118 6/20 0.57
RAB9A P51151 6/20 0.57
SMN1; SMN2 Q16637 2/20 0.54
GAA P10253 1/20 0.54
CYP1A2 P05177 1/20 0.53
NFKB1 P19838 1/20 0.53
STAT1 P42224 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53
DYRK1A Q13627 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31349449 0.86 KMT2A (0.68) ALDH1A1KMT2AMAPTNPC1RAB9A
SCHEMBL31349444 0.86 KMT2A (0.68) ALDH1A1KMT2AMAPTNPC1RAB9A
SCHEMBL1944598 0.85 KMT2A (0.72) SCDALDH1A1CYP2C19KMT2AMAPT
SCHEMBL2743007 0.84 KMT2A (0.72) SCDMMP13ALDH1A1KMT2AMAPT
SCHEMBL21552230 0.82 SCD (0.58) SCDMMP13ALDH1A1CYP2D6KMT2A
SCHEMBL4919533 0.81 SCD (1.00) SCDMMP13ALDH1A1CYP2C19CYP3A4
SCHEMBL10227093 0.81 KMT2A (0.57) SCDALDH1A1CYP2C19KMT2AMAPT
SCHEMBL4917926 0.79 CSNK1D (0.73) SCDMMP13ALDH1A1CYP2C19CYP3A4
SCHEMBL14375443 0.76 SCD (0.69) SCDMMP13ALDH1A1CYP2C19CYP3A4
SCHEMBL3490813 0.76 ALDH1A1 (1.00) SCDMMP13ALDH1A1CYP2C19CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180208575-A1 TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF PURDUE PHARMA L.P. 2018-07-26 US disclosed
US-9878991-B2 TRPV1 antagonists including dihydroxy substituent and uses thereof PURDUE PHARMA L.P. (US) 2018-01-30 US disclosed
US-9067928-B2 Compounds and methods of use ABBVIE INC. (US) 2015-06-30 US disclosed
US-9067928-B2 Compounds and methods of use ABBVIE INC. (US) 2015-06-30 US disclosed
US-9067928-B2 Compounds and methods of use ABBVIE INC. (US) 2015-06-30 US disclosed
EP-2376085-B1 COMPOUNDS AND METHODS OF USE GENENTECH INC (US) 2014-02-26 EP disclosed
EP-2376085-B1 COMPOUNDS AND METHODS OF USE GENENTECH INC (US) 2014-02-26 EP disclosed
US-20140005190-A1 COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2014-01-02 US disclosed
US-8518970-B2 Compounds and methods of use ABBVIE INC. (US) 2013-08-27 US disclosed
US-8518970-B2 Compounds and methods of use ABBVIE INC. (US) 2013-08-27 US disclosed
US-8518970-B2 Compounds and methods of use ABBVIE INC. (US) 2013-08-27 US disclosed
US-20120184541-A1 COMPOUNDS AND METHODS OF USE ABBVIE INC. 2012-07-19 US disclosed
US-20120184541-A1 COMPOUNDS AND METHODS OF USE ABBVIE INC. 2012-07-19 US disclosed
US-8114893-B2 Compounds and methods of use GENENTECH, INC. (US) 2012-02-14 US disclosed
US-8114893-B2 Compounds and methods of use GENENTECH, INC. (US) 2012-02-14 US disclosed
US-20100190782-A1 COMPOUNDS AND METHODS OF USE ABBVIE INC. 2010-07-29 US disclosed
US-20100190782-A1 COMPOUNDS AND METHODS OF USE ABBVIE INC. 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180208575-A1 TRPV1 ANTAGONISTS INCLUDING DIHYDROXY SUBSTITUENT AND USES THEREOF TRPV1, TRPA1, TRPV5 SCD 781/4885MMP13 4072/4885ALDH1A1 797/4885
US-20140005190-A1 COMPOUNDS AND METHODS OF USE BCL2A1, BCL2, BAX SCD 4498/4885MMP13 3046/4885ALDH1A1 3814/4885
US-20100190782-A1 COMPOUNDS AND METHODS OF USE BCL2A1, BCL2, BAX SCD 4498/4885MMP13 3046/4885ALDH1A1 3814/4885
US-20120184541-A1 COMPOUNDS AND METHODS OF USE BCL2A1, BCL2, BAX SCD 4498/4885MMP13 3046/4885ALDH1A1 3814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.